Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Glycoprotein (carbohydrate containing)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514002000 - Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20090093397PHASEOLUS VULGARIS EXTRACTS, THEIR USE, AND FORMULATIONS CONTAINING THEM - Extracts obtainable by extraction from 04-09-2009
20090170751Formation of superfibronectin by BBK32 and uses therefor - Provided herein is a method for inducing formation of a conformationally distinct superfibronectin by contacting plasma fibronectin with BBK32 protein or a BBK32 peptide and the BBK32-induced superfibronectin so formed. Also provided are methods of inhibiting endothelial cell proliferation, of treating pathophysiological conditions associated with endothelial cell proliferation and of inhibiting angiogenesis therein using the BBK32 protein, BBK32 peptide or the BBK32-induced superfibronectin.07-02-2009
20100056429TREATMENT OF RESPIRATORY CHAIN DISORDERS USING COMPOUNDS HAVING ERYTHROPOIETIN OR THROMBOPOIETIN ACTIVITY - Methods of treating mitochondrial respiratory chain disorders using compounds having erythropoietin activity or thrombopoietin activity are disclosed. Indicators for assessing the efficacy of treatment are discussed.03-04-2010
20090048155Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection - Methods for treating and preventing tissue injury and sepsis associated with a 02-19-2009
20100144600Osteoprotegerin variant proteins - The present invention relates to novel osteoprotegerin variant proteins (OVPs) that demonstrate reduce binding affinity for their ligand TRAIL when compared to wild-type osteoprotegerin. Nucleic acids which encode these OVPs are also provided. Recombinant vectors and host cells expressing these OVPs are also encompassed as are methods of producing recombinant OVPs. The present invention also relates to compositions comprising these OVPs, and to methods of treating bone diseases characterised by increased bone turnover and/or loss. The OVPs of the invention are useful for preventing bone resorption and may be used to treat any condition resulting in abnormal bone turnover or bone loss such as osteoporosis, hypercalcemia, Paget's disease of bone, multiple myeloma, bone cancer and bone loss due to rheumatoid arthritis or osteomyelitis, and the like.06-10-2010
20090192079PROLONGED DELIVERY OF HEPARIN-BINDING GROWTH FACTORS FROM HEPARIN-DERIVATIZED COLLAGEN - The present invention relates to a heparin-derivatized collagen matrix comprising a fragment of heparin covalently linked to a collagen scaffold, wherein the fragment of heparin has molecular weight of less than about 15 kDa, and at least one heparin-binding growth factor (HBGF) or heparin-binding adeno-associated virus (HB-AAV) or a combination thereof and methods for promoting bone growth, bone repair, cartilage repair, bone development, neo-angiogensis, wound healing, tissue engraftment and muscle tissue regeneration and/or tissue augmentation comprising administering a heparin-derivatized collagen matrix that includes at least one heparin-binding growth factor or heparin-binding adeno-associated virus or a combination thereof.07-30-2009
20090192078METHODS FOR DIAGNOSIS OF CARDIOVASCULAR DISEASE - This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.07-30-2009
20090192077North-2'deoxy -methanocarbathymidines as antiviral agents for treatment of kaposi's sarcoma-associated herpes virus - A method for the prevention or treatment of Kaposi's sarcoma or Kaposi's sarcoma-associated herpes virus infection by administering an effective amount of a cyclopropanated carbocyclic 2′-deoxynucleoside to an individual in need thereof is provided.07-30-2009
20100087362USE OF BIGLYCAN OR ENHANCERS OF BIGLYCAN ACTIVITY IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS - The present invention relates to the use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions having anti-atherosclerotic and anti-ischemic effect, and to the use of them in methods for preventing and treating the atherosclerotic and ischemid (e.g. cardiac) diseases. The invention also relates to screening methods by which biglycan or enhancers of biglycan activity can be identified.04-08-2010
20100081608Use of Human Chorionic Gonadotropin (hCG) by Oral-Sublingual or Injectable Route as an Appetite-Suppressant Agent. - Use of Human Chorionic Gonadotropin (hCG) by oral-sublingual or injectable route for the treatment of several food disorders, as an appetite-suppressant agent, food compulsiveness as well as all of those pathologies related to hunger and/or appetite modifications, including overweight, obesity, anorexia, bulimia, emotional hyperphagia, without excluding other pathologies associated to overingestion or reduced ingestion. It also includes its use for the treatment of behavior disorders associated with an increased ingestion, either behavior disorders, neurosis, borderline personality disorders or psychosis, without excluding other psychosomatic disorders.04-01-2010
20090023639Methods of Treatment - A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin B inhibitor; a β receptor blocker; an imidazoline receptor antagonist; a centrally acting α receptor antagonist; a peripherally acting α receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduces SNS activity such as an opiate; scopolamine; an endothelin receptor antagonist; and a xanthine oxidase inhibitor. The methods are particularly useful in treating cardiac cachexia.01-22-2009
20100048457GLYCOPROTEIN FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES - Provided is a glycoprotein product extracted from limax, wherein the preparation method of the glycoprotein product comprises the following steps: adding ethanol to the dry limax powders and removing the supernatant, extracting the resulting residue with water and then adding ethanol to the water extract for precipitating. The obtained glycoprotein product can be used for treating chronic obstructive pulmonary diseases (COPD) and has antibacterial and antiphlogistic effects.02-25-2010
20090209452SUBSTANTIALLY PURE GLYCOPEPTIDE ANTIBIOTICS AC-98-1; AC-98-2; AC-98-3; AC-98-4 AND AC-98-5 - The invention provides new substantially pure antibiotics designated AC-98-1, AC-98-2, AC-98-3, AC-98-4 and AC-98-5 derived from the microorganism 08-20-2009
20100041585USE OF ORITAVANCIN FOR PREVENTION AND TREATMENT OF ANTHRAX - Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against 02-18-2010
20100041588DERIVATIVES OF APF AND METHODS OF USE - Derivatives of a novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed. In particular embodiments, the glycopeptide comprises D-proline.02-18-2010
20100041586METHOD OF IMPROVING EFFICACY OF BIOLOGICAL RESPONSE-MODIFYING PROTEINS AND THE EXEMPLARY MUTEINS - Disclosed is a protein variant which substitutes valine for phenylalanine residue in a binding domain having a biological response-modifying function by binding to a receptor, ligand or substrate. Also, the present invention discloses a DNA encoding the protein variant, a recombinant expression vector to which the DNA is operably linked, a host cell transformed or transfected with the recombinant expression vector, and a method of preparing the protein variant comprising cultivating the host cell and isolating the protein variant from the resulting culture. Further, the present invention discloses a pharmaceutical composition comprising the protein variant and a pharmaceutically acceptable carrier.02-18-2010
20100041587COMBINATION THERAPY FOR INHIBITION OF PLATELET AGGREGATION - The invention features methods for preventing platelet activation and aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. The methods are based on the intravenous, subcutaneous, or transdermal administration of a platelet activation or aggregation inhibitor, e.g., xemilofiban, followed by oral administration of the same or a different platelet activation or aggregation inhibitor. The treatment may commence prior to a medical or surgical procedure or after the outbreak of an adverse medical condition, either of which results in the activation of platelets that may lead to thrombus formation, and may continue thereafter.02-18-2010
20090156470INTERFERING RNA DELIVERY SYSTEM AND USES THEREOF - The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.06-18-2009
20090156469METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF IN TREATING WALDENSTROM'S MACROGLOBULINEMIA - Disclosed are methods of treating Waldenstrom's Macroglobulinemia comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound of Formula I.06-18-2009
20090156468Use of human chorionic gonadotropin oral or injectable for metabolic syndrome treatment - To be used as a therapy for patients with one or more of the following clinical symptoms or laboratory findings: high blood pressure, diabetes type 2, reactive hyperglycemia, plasmatic hypertriglyceridemia, hypercholesterolemia and gout as part of the metabolic syndrome.06-18-2009
20090156467Thymic stromal lymphpoietin promoter and use therefor - A promoter comprising the isolated promoter region of the human Thymic Stromal Lymphopoietin (TSLP) gene and functional portions of the promoter region having TSLP promoter activity. The promoters are useful for identifying promoter agonists and antagonists that can be used to prevent or treat allergic conditions and autoimmune diseases.06-18-2009
20100105607NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS - Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi-synthetic glycopeptides described herein are made by chemical modification of the a glycopeptide (Compound A, Compound B, Compound H or Compound C) or the monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety on these scaffolds with certain acyl groups; conversion of the amide group in amino acid-3 on these scaffolds to various acylamide, acylsulfonamide, acylsulfonylurea derivatives; aminomethylation with substituent containing sulfonamide or acylsulfonamide group on amino acid-7 through Mannich reaction; and conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides. Also provided are methods for the synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections.04-29-2010
20100093606MRSA Bactericidal Topical Gel - I have combined Vancomycin at varying concentrations in a Calcium Alginate gel and treated open chronic wounds that cultured out MRSA. The response has been remarkable in the rapid cure of the involved wound. I have arrived at a 15% level of the Vancomycin as being an effective strength. The combined gel, if refrigerated, maintains it's effectiveness over three months. Only one to two applications results in negative cultures.04-15-2010
20100093607SYNERGISTIC THERAPEUTIC USE OF PROTHROMBIN COMPLEX CONCENTRATES WITH FVIII CONCENTRATES - The field of the invention is the treatment of acquired bleeding, a clinical condition associated with severe traumatic, perk or post-operative bleeding. A novel treatment is proposed in which synergistic procoagulatory properties of Prothrombin Complex Concentrates (PCC) together with medicaments comprising FVIII and/or vWF are exploited.04-15-2010
20090062182DEUTERIUM-ENRICHED DALBAVANCIN - The present application describes deuterium-enriched dalbavancin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-05-2009
20090042773P13 kinase gamma inhibitors for the treatment of anaemia - This present invention is related to the use of selective PD Kinase gamma inhibitors for the manufacture of a medicament for the treatment of disorders related to erythrocyte deficiency. Specifically, the present invention is related to the use of selective PI3 Kinase gamma inhibitors, e.g. substituted azolidinone-vinyl fused-benzene derivatives for the treatment of an anaemia, including haemolytic anaemia, aplastic anaemia and pure red cell anaemia. (I) wherein A, X, Y02-12-2009
20100120665TREATMENT OF DISEASES CHARACTERIZED BY INFLAMMATION - The invention provides, in part, methods, nucleic acids, vectors, proteins and binding molecules that can be used to modulate a pathway such as a complement pathway. These methods and compositions can be utilized, inter alia, for the study and/or treatment of various conditions or diseases related to a complement pathway.05-13-2010
20100130407FACILITATION OF RESUSCITATION FROM CARDIAC ARREST BY ERYTHROPOIETIN - The present invention relates generally to the use of erythropoietin (EPO) to facilitate resuscitation from cardiac arrest. For a mammalian subject suffering from cardiac arrest, concurrent administration of EPO with resuscitation after the onset of ventricular fibrillation facilitates the resuscitation. Administration of EPO serves to attenuate myocardial abnormalities caused by cardiac arrest and the resuscitation efforts and favor improved resuscitation outcomes. The main effect of EPO that facilitates resuscitation is the preservation of left ventricular myocardial distensibility leading to improve left ventricular preload and the amount of blood ejected by chest compression. This effect enables higher coronary perfusion pressures to be generated resulting in a higher rate of return of spontaneous circulation and higher survival rates. The very same effect enables the return of spontaneous circulation to occur faster reducing the time a human subject is in cardiac arrest. These effects lead to a higher number of cardiac arrest victims to survive and to do so with intact neurological function in most of the survivors.05-27-2010
20100130405BIGLYCAN AND RELATED THERAPEUTICS AND METHODS OF USE - The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.05-27-2010
20090305948Branched Polyamino Acids Functionalized with Hydrophobic Groups, and Applications Thereof Particularly Therapeutic Applications - The invention concerns novel materials based on biodegradable branched polyaminoacids particularly useful for transporting active principle(s). The invention also concerns novel pharmaceutical, cosmetic, dietetic or phytosanitary compositions based on polyaminoacids. The invention aims at providing a novel polymeric material, capable of being used for transporting active principle(s) and enabling all the required relevant specifications to be optimally satisfied: biocompatibility, biodegradability, easy ability to be combined with a large number of active principles or to solubilize same, and to release said active principles in vivo. This is achieved by the present invention which firstly concerns branched polyaminoacids comprising aspartic acid units and or glutamic acid units, and which bear hydrophobic groups including 8 to 30 carbon atoms. Said branched polyaminoacids are amphiphilic and are capable of being easily and economically transformed into particles for transporting active principles, said particles being themselves capable of forming stable aqueous colloidal suspensions.12-10-2009
20090305953DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS - The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of a mixture of dalbavancin multimers and monomers for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Compositions comprise a mixture of dalbavancin multimer and monomer and a stabilizer, such as dextrose.12-10-2009
20090305951COMPOUNDS CAPABLE OF AFFECTING DIFFERENTIATION, PROLIFERATION, REGENERATION, PLASTICITY AND SURVIVAL CELLS - The present invention relates to a compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, capable of interacting with an Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1, and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to a pharmaceutical composition comprising said compound, a process of producing a pharmaceutical composition and the use of said compound.12-10-2009
20090305950MULTIMER OF EXTRACELLULAR DOMAIN OF CELL SURFACE FUNCTIONAL MOLECULE - As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.12-10-2009
20090305949GLYCOSYLATED SPECIFICITY EXCHANGER - The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.12-10-2009
20090305952Anionic polyamide functionalized with a tryptophan unit - The invention relates to an anionic polyamide functionalized with at least one tryptophan unit, -Trp, said tryptophan unit being linked to the polyamide by an amide function separated from the backbone by a linker arm, the polyamide being a chain selected from the group constituted of the following polymers:12-10-2009
20090111737Novel antibacterial agents - This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands in their monovalent (i.e., unlinked) state have the ability to bind to a an enzyme involved in cell wall biosynthesis and metabolism, a precursor used in the synthesis of the bacterial cell wall and/or the bacterial cell surface thereby interfere with the synthesis and/or metabolism of the cell wall. In particular the multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands has 04-30-2009
20090111738FIBRONECTIN POLYPEPTIDES AND METHODS OF USE - Described herein are fragments of fibronectin and variants thereof that bind growth factors. Compositions containing such a fragment of fibronectin are therefore useful in sequestering growth factors, and complexes containing both a FN fragment and a bound, active growth factor can be used to deliver growth factors to a patient (e.g., to a wound on the patient's skin).04-30-2009
20090075868Synthetic peptide materials for joint reconstruction, repair and cushioning - In joint reconstruction, repair and cushioning applications, a synthetic polypeptide material is useful that contains cross-linked polypeptides that are modeled on human elastin or other fibrous proteins. The polypeptides comprise at least three consecutive beta-sheet/beta-turn structures and at least one amino acid residue that participates in cross-linking.03-19-2009
20090270310Process for the preparation of a nutrient formulation - The present invention relates to a process for increasing the efficacy and/or bioavailability of a nutrient formulation or composition for the treatment and/or prevention of inflammatory processes associated with airway diseases such as asthma. In particular, the invention relates to a method of treating an airway disease in a subject in need of such treatment, comprising the step of administering a nutrient formulation or composition which comprises one or more components which have been agitated such that a harmonic of between 20 to 50 Hz has been produced, in an amount effective to treat said disease.10-29-2009
20090036359Use of erythropoietin and substances increasing and/or prolonging the activation and/or stimulation of erythropoietin receptors for treating and/or preventing schizophrenia and related psychoses - Method for treatment and/or prophylaxis of schizophrenia and related psychoses of a human being, erythropoietin being administered to the human being.02-05-2009
20090029909Modulation of synaptogenesis - Soluble proteins, e.g. Hevin, can trigger synapse formation; and other soluble proteins, e.g. SPARC antagonize this activity. Such proteins are synthesized in vitro and in vivo by astrocytes. Methods are provided for protecting or treating an individual suffering from adverse effects of deficits in synaptogenesis, or from undesirably active synaptogenesis.01-29-2009
20090111736Orally-Absorbed Solid Dose Formulation for Vancomycin - An orally bioavailable pharmaceutical composition comprises at least 40% (w/w) vancomycin; a permeation enhancer component comprising 0.1 to 10.0% (w/w) of a polyoxyethylene sorbitan fatty acid ester; and a particulate carrier onto which the permeation enhancer component is adsorbed.04-30-2009
20100160212Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses - Modified human plasma polypeptides or Fc and uses thereof are provided.06-24-2010
20080214444SEMI-SYNTHETIC REARRANGED VANCOMYCIN/DESMETHYL-VANCOMYCIN-BASED GLYCOPEPTIDES WITH ANTIBIOTIC ACTIVITY - Semi-synthetic glycopeptides that have antibacterial activity are based on modifications of a rearranged vancomycin or desmethyl-vancomycin scaffold, in particular, alkylation or acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conversion of the acid moiety on the macrocyclic ring of this scaffolds to certain substituted amides. Also provided are methods for synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections.09-04-2008
20090069220DNA-BINDING POLYAMIDE DRUG CONJUGATES - A conjugate of formula:03-12-2009
20100144601Anti-TNF Alpha Fibronectin Type III Domain Based Scaffold Compositions, Methods and Uses - A protein scaffold based on a consensus sequence of the tenth fibronectin type III (FN3) repeat from human fibronectin, preferably human Tenascin, that binds to human TNFα including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.06-10-2010
20090029907Recombinant Method for Production of an Erythropoiesis Stimulating Protein - The present invention relates to the recombinant method used for the production of a highly glycosylated form (in total five N linked glycosylations as opposed to three N linked glyosylations in the natural EPO) of erythropoietin. The added sites for glycosylation will result in greater number of carbohydrate chains, and higher sialic acid content than human EPO, which in turn would impart to the recombinant molecule a longer half-life. The invention further relates to the construction of expression cassettes comprising nucleic acid sequences encoding for the highly glycosylated form of Erythropoietin and stable expression in the host cells. The invention further relates to the optimized method for purification of the erythropoiesis stimulating protein. The recombinant EPO according to the invention, and the salts and functional derivatives thereof, may comprise the active ingredient of pharmaceutical compositions for an increase in the hematocrit for treatment of anemia and for restoration of patient well being and quality of life.01-29-2009
20090105126Methods of Treating Pulmonary Disorders using Liposomal Vancomycin Formulations - The present disclosure relates in part to methods of treating and prevention of pulmonary disorders in a subject in need thereof comprising administering to the subject a liposomal vancomycin compositions having low lipid to drug ratios and high concentration of vancomycin.04-23-2009
20100173828A (X - 38 .. 43) oligomers, and processes, compositions, and uses thereof - The present invention relates to an Aβ(X-38 . . . 43) oligomer having a high molecular weight, or a derivative thereof, a process for preparing the oligomer or derivative, compositions comprising the oligomer or derivative, and uses of the oligomer or derivative such as its use for treating or preventing an amyloidosis (e.g. by active immunization), for diagnosing an amyloidosis, and for providing agents that are capable of binding to the Aβ(X-38 . . . 43) oligomer or derivative. The subject invention also describes agents that are capable of binding to the Aβ(X-38 . . . 43) oligomer or derivative, e.g. antibodies, compositions comprising the agents, and uses of the agents such as their use for treating or preventing an amyloidosis (e.g. by passive immunization) and for diagnosing an amyloidosis.07-08-2010
20090286717Glycopeptide Antibiotic Derivative - The present invention provides a novel glycopeptide antibiotic derivative.11-19-2009
20080249000Method of Modifying Gum Arabic, Modified Gum Arabic Obtained by the Method, and Use Thereof - An object of the present invention is to provide a method for enhancing the emulsification ability of gum arabic.10-09-2008
20080274950Cell Adhesion by Modified Cadherin Molecules - The potential role of so called ‘cell adhesion recognition motifs’ (CARs) in cadherin adhesion has been emphasized. Due to the importance of cadherin binding in biological process, there remains a need to develop effective ways of manipulating cadherin adhesion. According to the present invention, there is provided a pair of cadherin molecules modified to enhance intermolecular adhesion (i.e. adhesion or binding between the pair of cadherin molecules) compared with corresponding unmodified cadherin molecules. Intermolecular adhesion between the cadherin molecules may be enhanced by reducing or eliminating intramolecular binding within each cadherin molecule. For example, intramolecular binding may be reduced or eliminated by diminishing or preventing intramolecular binding of an N-terminal binding strand of each cadherin molecule with a binding strand acceptor pocket of each cadherin molecule. Additionally or alternatively, the intramolecular binding may be reduced or eliminated by diminishing or preventing the formation of an intramolecular ionic bond between the NH2 terminus of each cadherin molecule with a contact acidic amino acid residue of each cadherin molecule.11-06-2008
20090118162INHIBITORS OF SERINE PROTEASE ACTIVITY AND THEIR USE IN METHODS AND COMPOSITIONS FOR TREATMENT OF GRAFT REJECTION AND PROMOTION OF GRAFT SURVIVAL - Embodiments of the present invention illustrate methods of treating and preventing transplantation and side effects associated with transplantation. In particular, the present invention relates to compositions and methods for inhibition of graft rejection and promotion of graft survival. Thus, the invention relates to modulation of cellular activities, including graft rejection, promotion of graft survival, graft versus host rejection and conditions commonly associated with graft rejection. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease and inducers of other alpha1-antitrypsin activities.05-07-2009
20100099602PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY - The invention is directed to compositions and methods for using the same for the prevention and treatment of hypoxic conditions, ischemia/reperfusion injury and the sequels thereof.04-22-2010
20090181883HUMAN CHORIONIC GONADOTROPIN (hCG) FORMULATIONS FOR FACILITATING WEIGHT LOSS AND BODY CONTOURING - The present invention relates to formulations of hCG for sublingual administration to mammals to facilitate weight loss and/or body contouring. Embodiments of the invention disclose administration of hCG formulations in combination with a low calorie diet and dietary supplements and, in some cases, with an exercise regime. Embodiments of this invention also disclose transdermal hCG formulations and hCG formulations for administration through other administration routes.07-16-2009
20100035799METHOD FOR THE SYNTHESIS OF ANTHRACYCLINE-PEPTIDE CONJUGATES - The present invention relates to a method for the preparation of a compound of formula (I) or pharmaceutically acceptable salts thereof and intermediates thereof, comprising the steps of:02-11-2010
20090312240Synthesis of Sialic Acid in Plants - A method of synthesizing sialic acid in plants, and plants capable of synthesizing sialic acid is provided. Furthermore, a method of producing sialylated a protein in a plant is also provided. The method to synthesize sialic acid comprises providing a plant comprising a nucleotide sequence encoding N-acetyl neuraminic acid (Neu5Ac) synthase or Neu5Ac lyase, and expressing the nucleotide sequence thereby synthesizing sialic acid. The plant may also co-express a nucleotide sequence encoding one or more than one of an epimerase, a CMP-Neu5 Ac synthase, CMP-Neu5Ac transporter and a sialyltransferase.12-17-2009
20090099067Glycosylated G-CSF - The invention relates to G-CSF molecules having certain O-linked oligosaccharide structures.04-16-2009
20100113332METHOD OF TREATING AN INFLAMMATORY DISEASE BY DOUBLE STRANDED RIBONUCLEIC ACID - What is disclosed is the use of a formulation comprising double stranded ribonucleic acid (dsRNA) in the manufacture of a medicament for treating an inflammatory disease in a mammal and inhibiting production of tumor necrosis factor-α (TNF-α) in the mammal.05-06-2010
20100113334METHODS FOR REDUCING OR PREVENTING TRANSMISSION OF NOSOCOMIAL PATHOGENS IN A HEALTH CARE FACILITY - The present invention provides methods and compositions useful for reducing or preventing the transmission of nosocomial pathogens or an epidemic of nosocomial pathogens in a health care facility by decolonizing the gastro-intestinal tract, skin, or nasal passage of carriers and by preventing colonization of individuals at risk who may serve as transmission vehicles or vectors to other individuals.05-06-2010
20100113336THERAPEUTIC AGENT AND METHOD FOR OVULATION DISORDER CAUSED BY LUTEINIZED UNRUPTURED FOLLICLE - A therapeutic agent for ovulation disorder of the present invention is characterized in comprising Granulocyte colony-stimulating factor; and that the ovulation disorder is caused by Luteinized Unruptured Follicle.05-06-2010
20100113335COMPOSITIONS AND METHODS FOR TREATEMENT OF CANCER - The present invention discloses lentogenic viral strains useful in the treatment of cancer. A preferred viral strain of Newcastle disease Virus (NDV) is specifically characterized in terms of biological activities. The present invention further discloses treatment of cancer by application of a clonal NDV strain to tumors. According to an alternative preferred embodiment the use of at least one isolated viral protein or subunit or analog thereof, or an isolated polynucleotide encoding same, is used in the treatment of cancer.05-06-2010
20090325861DRY WOUND DRESSING AND DRUG DELIVERY SYSTEM - Dry dressings incorporate drug-delivery systems for anti-infective agents, growth factors, fibronectin or other substances to enhance tissue healing. A pharmaceutical composition includes hyaluronate polyvinylpyrrolidone (PVP), maltodextrin, and hydroxyethylcellulose and glycerin in the form of a membranous, wafer-like material after being freeze-dried.12-31-2009
20100120663METHOD FOR INDUCING THROMBOPOIESIS - A regime or regimen for inducing the differentiation of multilineage myeloid progenitor cells (CFU-GEMM) into megakaryocyte progenitor cells and, optionally, into megakaryocytes, that are able to produce platelets both in vivo and in vitro, includes a step a) of administering a thus effective amount of erythropoietin, derivative or agonist thereof to multilinear myeloid progenitor cells.05-13-2010
20100016216Adiponectin and uses thereof - The invention provides methods and reagents for regulation of metabolic events, such as those mediated by adiponectin and adiponectin agonists. The invention also provides screening assays for identification of biologically active agents, diagnostic and therapeutic agents, and other methods and reagents.01-21-2010
20100120666METHODS OF TREATMENT USING GLYCOPEGYLATED G-CSF - The present invention provides a glycopegylated G-CSF that is therapeutically active and which has pharmacokinetic parameters and properties that are improved relative to an identical, or closely analogous, G-CSF peptide that is not glycopegylated. Furthermore, the invention provides methods for mobilizing hematopoiesis in a subject, particularly a subject who has received or will receive radiation or chemotherapy treatment. The methods and compositions of the invention can further be used to prevent, alleviate and treat the myelosuppressive effects such therapies.05-13-2010
20100120664MODIFIED COAGULATION FACTORS WITH PROLONGED IN VIVO HALF-LIFE - The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences.05-13-2010
20100120667COMPOSITION FOR PREVENTING AND/OR TREATING PEPTIC ULCERS - A composition for effectively preventing or treating peptic ulcers not caused by 05-13-2010
20100081609PHARMACEUTICAL COMPOSITIONS CONTAINING A GLYCOPEPTIDE ANTIBIOTIC AND A CYCLODEXTRIN - Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.04-01-2010
20100125048COSMETIC COMPOSITIONS FOR SKIN-TIGHTENING AND METHOD OF SKIN-TIGHTENING USING THE SAME - The present invention relates to a skin-tightening cosmetic composition and a method of applying the same, and more specifically, to a cosmetic composition a method of applying the same that includes a hydrolyzed plant protein and glycoprotein. The cosmetic composition includes a hydrolyzed plant protein and glycoprotein in an optimal amount, thereby causing the occurrence of an immediate contraction effect and a long-lasting contracting effect, and achieving skin improvements such as skin moisturizing and induction of synthesizing collagen and elastine in use of the composition over a long period of time.05-20-2010
20100099603LYOPHILIZED RECOMBINANT VWF FORMULATIONS - The present invention provides long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.04-22-2010
20100125049POLYMER FACTOR VIII MOIETY CONJUGATES - Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.05-20-2010
20090275497METHOD FOR IDENTIFYING MODULATORS OF THE ACTIVITY OF ION-CHANNELS RECEPTORS - The present invention is directed to a method for selecting or identifying a compound capable of modulating the activity of an ion-channels receptor, such as GABA receptor, by measuring the calcium influx via the P2X receptor in presence of its agonist ATP when coupled to said ion-channels receptor in recombinant cells coexpressing these two receptors. The invention also concerns a kit or a device comprising the essentiel elements to perform the method according to the invention. Finally, the present invention is directed to the use of said selected compounds for the prevention or the treatment of diseases related to said ion-channels receptor dysfunction.11-05-2009
20080293622METHODS OF INDUCING OVULATION - The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.11-27-2008
20090088370Method for Improved Isolation of Recombinantly Produced Proteins - The present invention provides a method for increasing the yield of a protein produced by cultivating eukaryotic cells and adding an ionic substance to the culture medium prior to harvest of the protein. Suitable ionic substances are the salts of the Hofmeister series, amino acids and peptone.04-02-2009
20080207492Amphipathic Glycopeptides - Glycopeptides which are amphipathic and capable of crossing the blood-brain-barrier are provided. The glycopeptides are useful for treating a variety of neurological an behavioral disorders.08-28-2008
20100113333PHOSPHONATED GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS - The present invention is directed to antimicrobial compounds which have an affinity for binding bones. More particularly, the invention is directed to phosphonated derivatives of glycopeptide or lipoglycopeptide antibiotics. These compounds are useful as antibiotics for the prevention or treatment of bone and joint infections, especially for the prevention and treatment of osteomyelitis.05-06-2010
20090170752Reversal Of Adult Onset Disorders With Granulocyte-Colony Stimulating Factors - A method for treating adult onset neurodegenerative diseases and diabetes by administering an effective dose of Granulocyte-Colony Stimulating Factors.07-02-2009
20100137194Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism - The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.06-03-2010
20100137192COMPOSITIONS AND METHODS FOR TREATING OR AMELIORATING MYCOBACTERIAL INFECTIONS - A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram poitive and acid fast bacilli in general and tuberculosis (TB), 06-03-2010
20100137190LIQUID COMPOSITION FOR EXTERNAL APPLICATION AND PREPARATION FOR EXTERNAL APPLICATION FOR TREATMENT OF SKIN ULCER - An object of the present invention is to provide a liquid composition for external application and a preparation for external application which are excellent in healing effect on skin ulcers including intractable skin ulcers such as bedsore (decubitus), diabetic skin ulcer and ischemic skin ulcer. The liquid composition for external application of the present invention as means for the resolution is characterized by comprising at least G-CSF (a granulocyte colony stimulating factor) as an active ingredient and 0.001% to 5% of alginic acid. The preparation for external application for treatment of a skin ulcer of the present invention is characterized by comprising the liquid composition for external application of the present invention as a medicinal ingredient.06-03-2010
20080274949Formulation of Albumin-Free Erythropoietin - Disclosed is a stable pharmaceutical solution preparation of erythropoietin (EPO), which includes a stabilizing agent not containing a blood-derived protein, thereby maintaining EPO activity for a prolonged period of time without the risk of viral contamination. The stable solution preparation further includes a non-ionic surfactant and a tonicity agent, thereby preventing EPO loss during storage and facilitating administration to the body.11-06-2008
20080274948Conjugates of Hydroxyalkyl Starch and G-Csf - The present invention relates to conjugates of hydroxyalkyl starch and a granulocyte colony stimulating factor protein (G-CSF) wherein these conjugates are formed by a covalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. The present invention also relates to the methods of producing these conjugates and the use of these conjugates.11-06-2008
20100137191PROTECTIVE AGENTS FOR TRANSPLANTED ORGANS - Compositions for protecting transplanted organs, promoting survival of transplanted organs or preserving organs for transplant containing erythropoietin (EPO) as an active ingredient are provided.06-03-2010
20080280818GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES - The present invention provides sequon polypeptides with an amino acid sequence including one or more exogenous O-linked glycosylation sequence of the invention. In addition, the present invention provides methods of making polypeptide conjugates as well as methods of using such conjugates and their pharmaceutical compositions. The invention further provides libraries of sequon polypeptides, wherein each member of such library includes at least one exogenous O-linked glycosylation sequence of the invention. Also provided are methods of making and using such libraries.11-13-2008
20080293623ENRICHED HAPTOGLOBIN POLYMERS FOR THE TREATMENT OF DISEASE - Haptoglobin (Hp) removes cell-free Hemoglobin (Hb), with different physiological effects depending on the particular Hp polymer. We propose that material enriched for alpha 1 chain Hp polymeric forms, such as those made from Cohn fraction V precipitate, will be more suitable for the treatment of certain diseases benefiting from both an antioxidant and anti-inflammatory component, such as for hemolytic disease. Material enriched for alpha-2 chain Hp polymeric forms, made for example from Cohn fraction IV precipitate, will be more suitable for treatment of diseases where an angiogenic, and/or inflammatory affect, and/or limited extravasation is desirable.11-27-2008
20080293620Immunogenic Glycopeptides for Diagnosing Pathogenic Microorganisms Infections - A method for diagnosing an infection in a patient likely to be infected with a pathogenic microorganism, comprising the detection of CD4+ T lymphocytes recognizing at least one glycopeptide derived from said pathogenic microorganism, essentially consisting of a glycosylated T epitope, comprising from 14 to 25 amino acids, among which at least one neutral amino acid is bonded to a disaccharide or to a trisaccharide, and at least 15% of said amino acids are prolines, one of the prolines being located in position −1 to −4, relative to the position of said neutral amino acid.11-27-2008
20080305991Factor IX: remodeling and glycoconjugation of factor IX - The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.12-11-2008
20080305993Use of C1 Inhibitor for the Prevention of Ischemia-Reperfusion Injury - The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.12-11-2008
20080293621Methods for Prolonging Feline Life - Methods for prolonging feline life by maintaining a feline on a food having reduced levels of protein, phosphorus, and sodium when compared to a standard feline maintenance food.11-27-2008
20080312138Erythropoietin complementation or replacement - The present invention provides methods and compositions to replace up to 90% of erythropoietin use in the treatment of anemias and hypoxias. The method employs acid and salt forms of inositol-tripyrophosphate (ITPP) isomers to shift the P12-18-2008
20080312137Fed Batch Culture Methods for Streptococci - This invention relates to the optimization of culture conditions to improve the production of bacterial capsular polysaccharides from 12-18-2008
20080312139Use of Pharmaceutical Composition Containing Epidermal Growth Factor (EGF) for Diabetic foot Amputation Prevention - The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-Injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favouring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrisation of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine. Said composition can be used for recalcitrant ulcers which are associated with lesions in the macro and/or microvasculature, patients with inadequate lymphatic and/or venous return and ulcers or other lesions which are difficult to cicatrise and/or heal.12-18-2008
20080242597Antibiotic compounds - The present invention relates to novel thiazolyl peptide antibiotics capable of treating serious bacterial infections in mammals, and particularly, in humans. Some of the analogs can also be versatile intermediates for the preparation of new derivatives with useful antibacterial activity.10-02-2008
20100144605RESCUE OF GONADOTROPIN RELEASING HORMONE RECEPTOR MUTANTS - Herein disclosed is a method of rescuing gonadotropin-releasing hormone receptor (GnRHR) mutants with IN3 or a mimetic thereof. IN3 significantly rescues 11 missense mutations as assessed by radioligand binding and by IP production. Such rescue occurred despite widely disparate loci along the receptor. In addition, many altered GnRH receptors (terminally truncated, internal deletions, or lacking the ability to form bridges to form tertiary structure) were rescued with IN3.06-10-2010
20080269112Antineoplastic Agents Targeted via Glut Transporters - The present invention relates to novel antineoplastic agents and cancer diagnostic agents that specifically target neoplastic cells via the GLUT transportation system. More specifically, the invention relates to conjugates of 2-deoxyglucose, wherein a linker, which includes a covalent bond, is attached to 2-deoxyglucose at the 2 position, and the linker is attached to a therapeutic or diagnostic agent. The inventions also relates to methods of treating tumor disease and methods of making the novel compounds of the present invention. The agents of the present invention are superior to previous agents as they are targeted via GLUT transporters.10-30-2008
20090264341PURIFIED ARABINOGALACTAN-PROTEIN (AGP) COMPOSITION USEFUL IN THE TREATMENT PSORIASIS AND OTHER DISORDERS - A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of 10-22-2009
20090264339Heterocyclic Compounds - This invention relates to heterocyclic compounds of the formulas shown in the specification. It also relates to methods for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, and tissue injuries with one of the heterocyclic compounds.10-22-2009
20100137195Production of Recombinant IL-18 Binding Protein - The invention relates to a process for the production of IL-18 binding protein (IL-18BP), and to a composition comprising IL-18BP characterized by a specific glycosylation pattern.06-03-2010
20090029908UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS - Uteroglobin has been discovered to prevent IgA mediated diseases, such as IgA nephropathy, by preventing the deposition of IgA-Fibronectin immunocomplexes in tissues such as the renal glomeruli. The invention therefore includes methods of treating such diseases by administering therapeutically effective amounts of uteroglobin (and variants or mimetics) to prevent or improve the IgA mediated condition. Transgenic uteroglobin knockout animals, and animals in which uteroglobin-protein expression is reduced by antisense technology, also provide systems for studying IgA mediated diseases, and screening for appropriate treatments.01-29-2009
20100144598Natural Polypeptides For Oral Health Care - The present invention relates generally to dental diseases, caries and periodontal disease. More specifically, the invention relates to Lactoferrin and Statherin fusion proteins (STAT-LF) along with therapeutic, diagnostic and research uses for these polypeptides. The present invention also provides methods of treating dental diseases, caries and periodontal disease.06-10-2010
20090298748METHODS OF ADMINISTERING DALBAVANCIN FOR TREATMENT OF BACTERIAL INFECTIONS - The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of dalbavancin for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection.12-03-2009
20090298749DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS - The invention provides methods and compositions for treatment of bacterial infections. The composition may be a combination of factors, which include A12-03-2009
20090137461ABUSE-RESISTANT AMPHETAMINE PRODRUGS - The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.05-28-2009
20090137460Cross-linked glycopeptide-cephalosporin antibiotics - This invention provides cross-linked glycopeptide—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.05-28-2009
20090118164METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH - Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (R05-07-2009
20090054308Methods and Compositions for Treating Pulmonary Hypertension and Related Diseases and Disorders - Methods of treating pulmonary hypertension are disclosed. Particular methods comprise the administration of a tryptophan hydroxylase inhibitor and at least one other active pharmaceutical ingredient to patient in need thereof. Pharmaceutical formulations are also disclosed.02-26-2009
20090054306Photodynamic therapy using chemiluminescence and a ligand-photosensitiser conjugate - A method for destroying harmful cells is provided, applicable in treating proliferative diseases. The cells are destroyed by a combined treatment with a chemiluminescent agent and with a ligand-photosensitizer conjugate. The chemiluminescent agent emits light on reacting with oxygen species present in situ, the conjugate binds to the cell through its ligand and is activated by the emitted light, thereby destroying the cell. The method is demonstrated on a conjugate of transferrin-hematoporphyrin, which destroys cancerous cells in the presence of luminol.02-26-2009
20080318840Compositions of Alpha-Fetoprotein and Inducers of Apoptosis for the Treatment of Cancer - The invention relates to novel compositions comprising alpha-fetoprotein (AFP) and methods for preventing, treating or inhibiting a malignant neoplasm expressing an alpha-fetoprotein receptor (AFPR) with or without multidrug resistance. Compositions comprising a non-covalent complex of an exogenous AFP, and at least one apoptosis-inducing agent selected from the group comprising mitochondrial membrane permeabilizing agents, mitochondrial pore opening inducing agents, ionophores, caspase 9 activators, caspase 3 activators and retinoids, are provided, wherein the at least one apoptosis-inducing agent reversibly binds to the exogenous AFP. The invention also provides for a process for butanol extraction of porcine alpha-fetoprotein obtained from blood and amniotic fluid extracted during early embryogenesis.12-25-2008
20080318841Method For Preparing a Factor H Concentrate and the Use Thereof in the Form of a Drug - The invention relates to the use of a factor H for producing a drug for treating Uremic Haemolytic Syndrome (UHS), to a method for purifying the factor H from a frozen fresh plasma and to a factor H concentrate obtainable by said method.12-25-2008
20090247451Therapeutic Compositions for Age-Related Macular Degeneration - The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.10-01-2009
20090209453Glycoprotein Hormone Analogs - This invention relates to the field of glycoprotein hormone analogs and their uses as agonists, antagonists, targeting vectors, and immunogens. In particular, this invention describes a method for stabilizing a heterodimer that permits the preparation of functional glycoprotein hormone analogs. The analogs of present invention comprise at least one alpha subunit polypeptide and at least one beta subunit polypeptide, wherein the seatbelt region of the beta subunit is linked to the alpha subunit. The invention also provides for a beta subunit polypeptide wherein the C-terminal amino acid is from residue 10 to residue 20 of the seatbelt region.08-20-2009
20090023638SPILL RESISTANT ANTIBIOTIC FORMULATIONS - The disclosure is directed to a pharmaceutical kit with a first set, a second set and a third set of components. The first set of components can be a carbomer in an aqueous vehicle, the second set of components can be an antibiotic, and the third set of components can be a neutralizing agent. In exemplary embodiments, the first, second and third sets of components can be mixed together to form a spill resistant composition.01-22-2009
20090023637Methods for detecting and treating interstitial cystitis - The invention provides a method for diagnosing and inhibiting conditions associated with reduced amounts of THP and/or reduced amounts of total carbohydrate content in the THP, such as Interstitial Cystitis and its symptoms, and damaged mucin layers in a subject by administering an effective amount of a Tamm-Horsfall protein to the subject. The invention also provides a method for diagnosing Interstitial Cystitis in a subject by quantitatively determining in a sample, the level of THP, the amount of sialylation of Tamm-Horsfall protein and/or the total carbohydrate content in THP. A decrease in the amounts of THP, sialylation of Tamm-Horsfall protein and/or carbohydrate content in THP is indicative of Interstitial Cystitis.01-22-2009
20090023635Factor VII or VIIa - Like Molecules - Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.01-22-2009
20090118163Factor H for the Treatment of Chronic Nephropathies and Production thereof - The invention is directed to novel uses of Factor H, in particular in antibody-independent chronic nephropathies, e.g. in tubulointerstitial fibrosis (TIF). The invention is further directed to novel large scale manufacturing processes for Factor H.05-07-2009
20090054307PROPHYLACTIC AND THERAPEUTIC AGENTS AND USES THEREFOR - Treatment, detection and monitoring of disease of the nervous system, especially trauma or hypoxia, in particular in the central nervous system and the eye by up-regulation or increasing levels of Ndfip1 (also known as Nedd4-WW Domain Binding Protein 5 or N4WBP5). Prophylaxis of such conditions in pre-term infants, coronary artery bypass graft, chemotherapy, tumor irradiation and other patients.02-26-2009
20090203580Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity - Embodiments herein illustrate methods and compositions for treating medical disorders. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating graft rejection, transplant rejection or diabetes in a subject. Other embodiments herein relate to compounds including naturally occurring and synthetic mutant compositions of alpha-1 antitrypsin, wherein the alpha-1 antitrypsin has no significant serine protease inhibitor activity.08-13-2009
20090197797USE OF HYALURONIC ACID AS A CARRIER MOLECULE FOR DIFFERENT CLASSES OF THERAPEUTIC ACTIVE AGENTS - The present invention refers to a drug delivery system consisting of hyaluronic acid and a therapeutic active agent.08-06-2009
20090137459Food Product for Enteral or Oral Nutrition - This invention relates to a food product for enteral or oral nutrition, comprising a novel protein mixture, a novel lipid mixture, as well as carbohydrates, soluble and insoluble fibre, vitamins and minerals, composing a nutritional product adequate for pathologic conditions where there is some kind of impairment to meet nutritional needs with a normal oral diet.05-28-2009
20080261868Methods and Compositions for Treating Diabetes - The instant invention provides a method of treating an animal suffering a disease characterized by excessive apoptosis by administering a therapeutically effective amount of at least one serine protease inhibitor and thereafter monitoring a decrease in apoptosis. The inhibitor of the invention includes α10-23-2008
20080261867Soluble inhibitors of vascular endothelial growth factor and use thereof - The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF10-23-2008
20080261866Compositions Comprising Glycosaminoglycan and Nonsteroidal Anti-Inflammatory Drug - Pharmaceutical compositions comprising of glycosaminoglycan or salts thereof, preferably chondroitin or salts thereof, more preferably chondroitin sulphate, and nonsteroidal anti-inflammatory drug(s) or salts thereof, optionally with pharmaceutically acceptable excipient(s) are described. The compositions of the present invention provide gastrosparing effect in conditions where nonsteroidal anti-inflammatory drug(s) or their salts are used, particularly in mammals. Also provided are process for the manufacture of such novel compositions and method to minimize the nonsteroidal anti-inflammatory drug(s) induced gastric toxicity.10-23-2008
20080261865Oxidized Lipids and Uses Thereof in the Treatment of Inflammatory Diseases and Disorders - Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.10-23-2008
20090209455VITREOUS ADMINISTRATION OF ERYTHROPOIETIN - A therapeutic composition for treating and/or preventing retinal disorder includes intravitreally or transsclerally administered erythropoietin.08-20-2009
20090209454METHOD FOR PURIFYING FSH OR A FSH MUTANT - The invention relates to a method for purifying a glycoprotein, preferably FSH or a FSH mutant comprising the steps of subjecting a liquid containing said FSH or a FSH mutant to: (1) a dye affinity chromatography; (2) a weak anion exchange chromatography; (3) a hydrophobic interaction chromatography; and (4) a strong anion exchange chromatography; which may be carried out in any order.08-20-2009
20090221470USE OF AN ECHINOCANDIN ANTIFUNGAL AGENT IN COMBINATION WITH A GLYCOPEPTIDE ANTIBACTERIAL AGENT - This invention is directed to methods of administering an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms. The invention is also directed to methods of using an echinocandin antifungal agent in combination with a specified glycopeptide antibacterial agent to treat fungal infections; and to compositions, kits and systems comprising an echinocandin antifungal agent and a specified glycopeptide antibacterial agent.09-03-2009
20090221471PRODRUGS OF VANCOMYCIN WITH HYDROLYSIS RESISTANT POLYMER LINKAGES - Vancomycin-polymer conjugates are disclosed. In preferred aspects, polymer residues which are hydrolysis resistant in vitro, are selectively attached to the sugar amino and/or N-methyl amino groups of vancomycin and related compounds. Vancomycin-polymer conjugates made by the methods and methods of treatment using the conjugates are also disclosed.09-03-2009
20090264340COMPOSITIONS AND METHODS FOR INCREASING THE ORAL ABSORPTION OF ANTIMICROBIALS - The present invention provides compositions and methods for increasing absorption of antibacterial agents, particularly third generation cephalosporin antibacterial agents, in oral dosage solid and/or suspension forms. Specifically, the composition is comprised of a biopolymer that is preferably swellable and/or mucoadhesive, a antimicrobial agent, and a cationic binding agent contained within the biopolymer such that the binding agent is ionically bound or complexed to at least one member selected from the group consisting of the biopolymer and the antimicrobial agent.10-22-2009
20090239790NOVEL RECOMBINANT PROTEINS WITH N-TERMINAL FREE THIOL - The present invention relates to novel modified proteins having N-terminal free thiols that can be produced by recombinant methods and are ready for further chemical derivatization. In particular, the invention relates to erythropoietin conjugate compounds having altered biochemical, physiochemical and pharmacokinetic properties. More particularly, one embodiment of the invention relates to erythropoietin conjugate compounds of the formula:09-24-2009
20090239787SELF-FOAMING CEMENT FOR VOID FILLING AND/OR DELIVERY SYSTEMS - A self-foaming bone cement is described herein. In one variation, the bone cements include a self setting calcium phosphate cement formulation which when cured, forms macroscopic pores of varying sizes and densities with sufficient surface area to provide substantial regions for bone turnover.09-24-2009
20100016217DERIVATISATION OF GRANULOCYTE COLONY-STIMULATING FACTOR - The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.01-21-2010
20100152098POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF - Disclosed are compounds having polybasic functionalities. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.06-17-2010
20100167991Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative - The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates to a pharmaceutical composition, wherein the active principle is chosen from the group consisting of proteins, glycoproteins, peptides and nonpeptide therapeutic molecules. The invention also relates to the use of the functionalized polysaccharides according to the invention in the preparation of pharmaceutical compositions as described above.07-01-2010
20100173831FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.07-08-2010
20100210509LONG ACTING HYALURONIC ACID - PEPTIDE CONJUGATE - The invention relates to a novel bioconjugation protocol for peptide suitable for in vivo applications. Bioconjugation of the peptide to HA derivative increases its half life in circulation contributing for a high efficacy. More over, conjugate of HA derivative and peptide which is treated with hyaluronidase shows increased bioactivity. And also, in contrast to PEGylation, HA derivative can be conjugated with many numbers of peptide molecules per single HA derivative chain, which enables multiple action of peptide drugs.08-19-2010
20100184643Methods and Compounds Regulating the Erythroid Response to Iron Deficiency - The present invention discloses the signaling pathway involved in erythroid repression by iron deficiency. Further disclosed is a non-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakary-ocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.07-22-2010
20100184644MUCOSAL REPAIR BY TFF DIMER PEPTIDES - The present invention relates to the use of trefoil factor 1 (TFF1) and trefoil factor 3 (TFF3) dimers and a pharmaceutical composition comprising TFF dimers for increasing the viscosity of mucin in mucus layers and the repair of damaged mucus layers in the gastrointestinal tract (mouth, oesophagus, stomach, small and large intestine, colon) the respiratory passages, the eye, the urinary system (including the bladder) and the cervis uteri.07-22-2010
20100184642Transgenic Plants Expressing Cobalamin Binding Proteins - The present invention relates to the use of transgenic plants for the expression of vitamin B12 (cobalamin) binding proteins. Plant cells are transformed with nucleotide sequences adapted for expression and secretion of vitamin B12 binding proteins. The present invention also relates to the use of recombinant vitamin B12 binding proteins from plants in analytical tests and treatment of vitamin B12 deficiency. Also disclosed is a method for purification of recombinant vitamin B12 binding proteins.07-22-2010
20100216697PHARMACEUTICAL COMPOSITION, SUBSTRATE COMPRISING A PHARMACEUTICAL COMPOSITION, AND USE OF A PHARMACEUTICAL COMPOSITION - The invention relates to the use of a pharmaceutical composition for the local treatment or prevention of a tissue infection at an infection site, the pharmaceutical composition comprising at least two different antibiotics of group A or pharmaceutically acceptable derivatives thereof, or an antibiotic of group A and at least one antibiotic of group B or pharmaceutically acceptable derivatives thereof. Group A comprises primarily intracellular active antibiotics working as inhibitor of bacterial RNA polymerase; as inhibitor of gyrase; or as inhibitor of bacterial protein synthesis. Group B comprises primarily extracellular active antibiotics working as inhibitor of bacterial cell wall synthesis; or inhibitor of bacterial protein synthesis; or by direct destabilisation or rupture of the bacterial cell wall.08-26-2010
20100227798USE OF THE STAUDINGER LIGATION IN IN VIVO ASSEMBLY OF A BIOLOGICALLY ACTIVE COMPOUND - The invention provides methods and tools for the in vivo self-assembly of drugs. This makes it possible to reduce problems associated with the lack of selectivity, reduced solubility and other disadvantages of intact drugs.09-09-2010
20100216696Compounds and methods for treating cancer - The present invention provides a method of treating cancer involving administering an insulin-like growth factor-1 receptor (IGF-1 receptor) agonist and an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an IGF-1-receptor ligand coupled to an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an insulin-receptor ligand coupled to an anti-cancer chemotherapeutic agent.08-26-2010
20100227799SIMULTANEOUS PHOTODYNAMIC THERAPY AND PHOTO INDUCED POLYMERIZATION - Described herein are methods and compositions for the combined treatments of photodynamic therapy and photo-induced polymerization. The wavelength of light needed to accomplish both therapies can be different or can be the same. In one embodiment, the photodynamic therapy is performed first and the photo-induced polymerization is performed thereafter. In other embodiments, both treatments are performed simultaneously.09-09-2010
20100216699SEMI-SYNTHETIC GLYCOPEPTIDES HAVING ANTIBACTERIAL ACTIVITY - Semi-synthetic glycopeptides having antibacterial activity are described. Also described are processes of preparing such semi-synthetic glycopeptides by chemical modification of a glycopeptide (Compound A, Compound B, Compound H or Compound C) or the monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in mild acidic medium to give the amino acid-4 monosaccharide; protection of the amino groups in the molecule; and conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides. Also included are the process of conversion of the amide group in amino acid-3 on these scaffolds to various acylureas, acylamide, acylsulfonamide, acylsulfonylurea derivatives and aminomethylation with substituent containing sulfonamide or acylsulfonamide group on amino acid-7 through Mannich reaction procedures. Further provided herein are pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, including bacterial infections.08-26-2010
20100144602Methods of Inhibiting Metastatic Cancer by Administration of Streptolysin O - The invention provides a method for administering streptolysin O for treatment of various conditions including connective tissue disorders, reproductive fibroses and conditions mediated by the CD44 receptor. The invention also provides methods for protecting nerve cells from the effects of neurotoxic agents by the administration of streptolysin O.06-10-2010
20100210512THYROID-STIMULATING HORMONE RECEPTOR POLYPEPTIDE AGONIST GLYCOFORMS TO TREAT METABOLIC SYNDROME - TSHR agonists that are substantially desialylated are described for treating metabolic syndrome and obesity and for inducing lipolysis. The TSHR polypeptide agonists are useful for treatment of hallmarks of metabolic syndrome: obesity, insulin resistance, hyperlipidemia, and liver steatosis, without producing a hyperthyroid state in treated individuals.08-19-2010
20090105127Methods for stabilizing corneal tissue - Methods of stabilizing collagen fibrils in a cornea are disclosed. The stabilization may be effected by treating the cornea with a protein that crosslinks collagen fibrils, such as decorin. The stablization methods include treatment of corneas before, during, or after a surgical procedure, treatment of keratectasia, and treatment of keratoconus.04-23-2009
20100144599VEGF PATHWAY BLOCKADE - The present invention relates to innovative proteins that block the VEGF-VEGFR pathway mediated biology and pathology, as well as pharmaceutical formulations of these proteins. The invention also relates to dosage therapies for the administration of these proteins. The invention further relates to the use of VEGF-A as a biomarker for determining an effective dosage and predicting the efficacy of these proteins.06-10-2010
20100144604Novel cellular factor-containing solution compositions - The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.06-10-2010
20090075867Triazine compounds and compositions thereof for the treatment of cancers - Compounds useful in the treatment of metastatic melanoma and other cancers containing a triazine ring scaffold are described. These compounds may be classified into two groups: (1) two disubstituted triazine rings are covalently linked by an organic linker to each other and (2) one trisubstituted triazine ring.03-19-2009
20100222252DESHYDROXY VANCOMYCIN, THE PREPARATION, PHARMACEUTICAL COMPOSITION AND THE USE - The present invention provides a deshydroxy vancomycin compound,a method of its preparation and a pharmaceutical composition comprising a pharmaceutically effective amount of the deshydroxy vancomycin and the use of the said composition in the preparation of drugs for the treatment of susceptible bacteria infections. The method includes the following steps: (1) preparing a concentrated vancomycin solution containing the deshydroxy vancomycin by fermentations of 09-02-2010
20100210513RNAi Inhibition of Alpha-ENaC Expression - The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.08-19-2010
20100210510ORAL LACTOFERRIN IN THE TREATMENT OF SEPSIS - The present invention relates to methods of treating prophylactically or therapeutically bacteremia, sepsis, septic shock or related conditions such as ARDS by administering orally a composition of lactoferrin alone or in combination with standard therapies or metal chelators to prevent or treat the consequences of bacterially induced systemic inflammatory response syndrome. In particular it is claimed that the therapeutic use of recombinant human lactoferrin alone or in combination with metal chelators or other therapeutic interventions decreases the mortality due to bacteremia, sepsis, septic shock or related conditions such as ARDS.08-19-2010
20100210514RNAi Inhibition of Alpha-ENaC Expression - The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.08-19-2010
20100210511Combination VEGFR2 Therapy with Temozolomide - The present disclosure relates to improved methods of treating neoplastic disorders by combining VEGFR2 specific inhibitor treatment with temozolomide. In particular, methods for treating glioblastoma with a combination of a VEGFR2 inhibitor and temozolomide are provided.08-19-2010
20100222254STABILIZATION OF CLOSTRIDIUM BOTULINUM NEUROTOXIN COMPLEX - A stable composition including a non-covalent complex of a botulinum neurotoxin and a cyclodextrin and a method of preserving botulinum neurotoxin and for producing a botulinum neurotoxin composition with improved stability properties in an efficient and economically advantageous manner. The invention seeks to alleviate the problems associated with rapid degradation or denaturation of botulinum neurotoxin by providing a novel composition that exhibits improved stability properties. The botulinum neurotoxin is preferably stabilized by forming a cyclodextrin complex.09-02-2010
20100197569CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS - This invention provides cross-linked glycopeptide—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.08-05-2010
20100197568PROTECTIVE HYDROCOLLOID FOR ACTIVE INGREDIENTS - Partially deamidated rice endosperm protein or rice endosperm protein which is partially conjugated with mono-, di-, oligo- or polysaccharides is used as novel protective hydrocolloid for fat-soluble active ingredients and/or fat-soluble colorants. The present invention further includes compositions comprising that rice endosperm protein and at least one fat-soluble active ingredient/colorant, as well as their manufacture, that rice endosperm protein itself and its manufacture. These compositions are used for the enrichment, fortification and/or coloration of food, beverages, animal feed, personal care or pharmaceutical compositions. The present invention is directed to theses uses and to food, beverages, animal feed, personal care and pharmaceutical compositions containing such a rice endosperm protein and such a composition, respectively.08-05-2010
20090203579Glycopegylated Granulocyte Colony Stimulating Factor - The present invention provides conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.08-13-2009
20090111740USE OF THERAPEUTIC HUMAN ALBUMIN FOR THE PREPARATION OF A DRUG FOR THE TREATMENT OF PATIENTS SUFFERING FROM COGNITIVE DISORDERS - The present invention relates to the use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders. In particular, the invention relates to methods of treating patients suffering from cognitive disorders, in which the mode of administration of the drug comprises the administration to the patient for a minimum of three successive times of a therapeutically effective amount of human therapeutic albumin by plasma exchange and/or intravenous perfusion, independently of the content of Aβ in the patient's blood.04-30-2009
20080305992Glycopegylated erythropoietin - The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.12-11-2008
20090111739SUGAR CHAIN ADDED GLP-1 PEPTIDE - The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog.04-30-2009
20100144603METHODS AND USES THEREOF OF PROSAPOSIN - The invention relates to methods for treating of tumor metastasis, methods for preventing, inhibiting, and predicting tumor recurrence and tumor metastasis, and methods of preventing cancer development for one at risk of developing cancer, for one diagnosed with a benign cancer, and/or for one diagnosed with malignant cancer. The invention also relates to methods of treating angiogenesis-dependent diseases and disorders. In addition, the invention provides: (1) a method for screening for tumor/cancer derived angiogenesis and metastasis factors; (2) a method for screening for compounds that inhibit angiogenesis and metastasis; (3) a method for screening for compounds that promote anti-angiogenesis and anti-metastasis activities; (4) a method for cancer prognosis evaluation; (5) a method for predicting the tissue specificity of a metastatic cancer; (6) a method for determining likelihood of metastasis; and (7) a method for cancer prognosis evaluation by the surveillance of metastasis development.06-10-2010
20100029549SITU SELF-SETTING MINERAL-POLYMER HYBRID MATERIALS, COMPOSITION AND USE THEREOF - The present invention relates to self-setting compositions consisting in admixed liquid and solid components enable the formation of hardened bio-materials having a broad range of properties and performances. The present invention proposes a) a thermo-sensitive self-gelling liquid component, being water-based, comprising at least a polycationic and a phosphate source, wherein the liquid component is a thermo-gelling solution at a pH ranging from 6.5 to 7.4; b) a powder component consisting in at least two calcium phosphate sources. The preferred calcium phosphate source includes apatites, tricalcium phosphates, tetracalcium phosphates and dicalcium phosphates. Both solid and liquid components are admixed to form a flowable slurry that sets in situ into a hardened calcium phosphate based bio-material.02-04-2010
20090088371COMBINATION THERAPY WITH SYK KINASE INHIBITOR - The invention encompasses methods of increasing platelet levels in a patient having or at risk for immune thrombocytopenia comprising co-administering a Syk kinase inhibitor and a thrombopoietin receptor agonist, and methods of treating thrombocytopenia comprising co-administering a Syk kinase inhibitor and a thrombopoietin receptor agonist to a patient in need thereof, as well as pharmaceutical compositions for use in these methods.04-02-2009
20100179091Treatment of Conditions Related to Shock - Techniques are disclosed for prevention or treatment of physiological shock by administering a specific therapeutic agent or combination of therapeutic agents, which is/are able to use smaller volumes of reagent to achieve complete inhibition, than other previously described techniques.07-15-2010
20100056428MODIFIED PROTEINS - Method of conjugating glycoproteins by means of chemical modification is provided as well as new modified glycoproteins.03-04-2010
20100056427N-TERMINAL DERIVATISATION OF PROTEINS WITH POLYSACCHARIDES - The present invention relates to methods for producing N-terminal derivatives of proteins in which a polysaccharide, preferably having at least terminal sialic units and preferably consisting essentially only of sialic acid units, is reacted at the N-terminus of a protein or peptide under controlled conditions to produce an N-terminal derivative. The controlled conditions include use of acidic pH for the derivatisation step and a higher pH for purification. The derivatives are useful for improving pharmacokinetics and pharmacodynamics of proteins and peptides.03-04-2010
20090215671Compositions And Methods For Treatment of Neural Disorders Using Transforming Growth Factor-Beta Superfamily Proteins And Their Antagonists - Contemplated compositions and methods employ a TGF-beta superfamily protein or antagonist thereof to treat a neural disorder characterized by an imbalance in differentiated functional sensory and neural cells derived from a sensory/neural progenitor cell. Preferably, GDF-11 and/or antagonists thereof are employed in the treatment of diseases in which visual and/or auditory progenitor cells will provide for a repair mechanism to the disease. Most preferably, GDF-11 is employed as a modulator of competency to increase production of retinal ganglion cells, retinal photoreceptors, retinal amacrine cells, sensory hair and supporting cells of the vestibulocochlear epithelium, and/or neurons and supporting cells of the spiral acoustic ganglion and vestibulo-cochlear (auditory) nerve to which it gives rise.08-27-2009
20090215674USE OF A POLYENE MACROLIDE ANTIFUNGAL AGENT IN COMBINATION WITH A GLYCOPEPTIDE ANTIBACTERIAL AGENT - This invention is directed to methods of administering a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms. The invention is also directed to methods of using a polyene macrolide antifungal agent in combination with a specified glycopeptide antibacterial agent to treat fungal infections; and to compositions, kits and systems comprising a polyene macrolide antifungal agent and a specified glycopeptide antibacterial agent.08-27-2009
20090215673PROCESS FOR PURIFYING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES - Disclosed are methods of purifying glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups that are useful as antibacterial agents. The methods include contacting a solution of the glycopeptide derivatives with a polystyrene-containing resin, eluting the resin with an aqueous solution, and isolating the purified glycopeptide derivative.08-27-2009
20090215672Cys-Rich, Cell Surface Glycoproteins - This invention relates to novel proteins, termed INSP206 and INSP208 herein identified as Cys-rich, cell surface glycoproteins, and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.08-27-2009
20100062974COMBINATION THERAPY FOR THE TREATMENT OF BACTERIAL INFECTIONS - The invention features a method for treating a subject diagnosed with, or at risk of developing, a bacterial infection by administering to the subject a combination of biologically active agents.03-11-2010
20100062973Production of bioactive glycoproteins from inactive starting material - A method for preparing a conjugate comprising a glycoprotein and a polymer or a derivative of said polymer, wherein the polymer is a hydroxyalkylstarch (HAS), the method comprising the steps a) reacting said glycoprotein with a modified polyol carrying attached thereto, by a covalent linkage, a functional group Z, in the presence of a transferase capable of catalysing formation of a covalent linkage between the glycoprotein and said modified polyol, yielding a glycoprotein covalently linked to a polyol carrying attached thereto, by a covalent linkage, at least one functional group Z, and b) reacting at least one functional group A of the polymer or the derivative thereof with the at least one functional group Z of the glycoprotein added to said glycoprotein during step a), and thereby forming a covalent linkage.03-11-2010
20100022443DERIVATISATION OF ERYTHROPOIETIN (EPO) - The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.01-28-2010
20090239789METHODS OF TREATMENT WITH DRUG LOADED POLYMERIC MATERIALS - Polymeric microparticles have been developed which encapsulate therapeutic compounds such as drugs, cellular materials or components, and antigens, and can have targeting ligands directly bound to the microparticle surface. Preferred applications include use in tissue engineering matrices, wound dressings, bone repair or regeneration materials, and other applications where the microparticles are retained at the site of application or implantation. Another preferred application is in the use of microparticles to deliver anti-proliferative agents to the lining of blood vessels following angioplasty, transplantation or bypass surgery to prevent or decrease restenosis, and in cancer therapy. In still another application, the microparticles are used to treat or prevent macular degeneration when administered to the eye, where agents such as complement inhibitors are administered.09-24-2009
20090118161TREATMENT OF MEDICAL CONDITION WITH A2 DOMAIN OF VON WILLEBRAND FACTOR - The present invention is directed to methods for the prevention, treatment and/or diagnosis of a medical condition, such as sepsis, systemic inflammatory reaction syndrome, and/or thrombosis, for example. In particular, the method employs part or all of the A2 domain of von Willebrand factor. In certain cases, a recombinant A2 domain is utilized for the treatment of sepsis, systemic inflammatory reaction syndrome, and/or thrombosis, for example.05-07-2009
20080214443Compositions and Methods for Control of Insect Infestations in Plants - The present invention is directed to controlling pest infestation by inhibiting one or more biological functions in an invertebrate pest. The invention discloses methods and compositions for use in controlling pest infestation by feeding one or more different recombinant double stranded RNA molecules to the pest in order to achieve a reduction in pest infestation through suppression of gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, and to particular combinations of transgenic pesticidal agents for use in protecting plants from pest infestation.09-04-2008
20080214442Anti-Viral Effect of an Extract of Ganoderma Lucidum - Compositions and methods for the treatment viral infections in organisms, particularly flu virus. The methods and compositions of the disclosure involve the administration to mammals and immune cells of a fucose-containing glycoprotein fraction from Reishi. An extract of 09-04-2008
20090143281THROMBOMODULIN ANALOGS FOR USE IN RECOVERY OF SPINAL CORD INJURY - The present invention relates to the use of thrombomodulin analogs for the treatment of trauma-induced spinal cord injury.06-04-2009
20080312136Alpha 1-Antitrypsin Compositions and Treatment Methods Using Such Compositions - Alpha 1-antitrypsin compositions and treatment methods using such compositions for treating a variety of pulmonary diseases are provided. The compositions generally contain AAT, a stabilizing carbohydrate such as trehalose, a surfactant such as Polysorbate 80 and an antioxidant to stabilize AAT for use as a therapeutic. The formulations can be prepared as both liquids and solids and administered by nebulization of the liquid formulation or by conversion of dry powder formulation into an aerosol.12-18-2008
20090176697Method to obtain the human Chorionic Gonadotropin (hCG)/cyclodextrin complex for oral administration, product obtained by this method and clinical and therapeutic use of the complex human Chorionic Gonadotropin (hCG)/cyclodextrin - To inform about the clinical utility human Chorionic Gonadotropin (hCG) complexed with cyclodextrins for oral administration, its utility in different pathologies and method for obtaining it.07-09-2009
20100190692METHODS FOR REDUCING GNRH-POSITIVE TUMOR CELL PROLIFERATION - A method for recognizing and evaluating the presence and function of GnRH receptors on tumor cells originating in the brain and/or nervous system and/or the meninges and/or reactive neuroglia cells and/or primitive neuroectodermal tumor cells and/or on Kaposi sarcoma is provided. Furthermore a method for reducing degenerate GnRH-positive tumor cells and/or for decreasing cellular replication of the above GnRH-positive tumor cells comprising administering to a cell or to a subject a replication decreasing amount of a GnRH agonist and/or GnRH antagonist and/or an erythropoietin agonist, and/or a thrombopoietin agonist, and/or a endothelin antagonist and/or a gonadotropin inhibiting hormone agonist is also provided. Furthermore, a diagnostic kit for detecting GnRH receptors on tumor cells according to the present methods is disclosed.07-29-2010
20100190691DELIVERY OF NUCLEIC ACIDS USING CELL-PENETRATING PEPTIDES - The present invention is based on the innovative concept of conjugating a cell-penetrating peptide (CPP), including a protein transduction domain, to a nucleic acid molecule to provide a nucleic acid-protein conjugate exhibiting enhanced cellular uptake. Accordingly, the invention provides a method of producing a cell permeable nucleic acid molecule conjugate nucleic acid including a nucleic acid conjugated with a homeodomain of an antennapedia homeotic transcription factor protein (Antp), or functional fragment thereof. The invention further provides compositions and methods treating a subject using the conjugates produced by the method described herein.07-29-2010
20100190690BIOMIMETIC PARTICLES AND FILMS FOR PATHOGEN CAPTURE AND OTHER USES - The identification and immobilization of glycosylated molecules having biomimetic properties, more particularly naturally-occurring, tissue-derived, non-immunological glycan sequences or functional equivalents thereof, on solid state surfaces and films or on membranes arising at the interface between non-polar and polar materials is described herein. The biomimetic glycosylated films and particles constructed therefrom have industrial, environmental, diagnostic and/or therapeutic utility in the binding, capture, and/or extraction of pathogens, toxins and/or contaminants, in vivo, in vitro or in situ. The present invention further extends to the use of such biomimetic films and particles for the delivery of other therapeutic molecules as well as in the construction of body contacting devices having enhanced biocompatibility and reduced immunogenicity.07-29-2010
20100190689COMPOSITIONS AND METHODS RELATED TO PROTEIN DISPLACEMENT THERAPY FOR MYOTONIC DISTROPHY - Disclosed are compositions and methods related to the interaction of polyCUG and polyCCUG repeat RNA and proteins that bind to these repetitive RNA sequences. Also disclosed are methods of treating DM1 or DM2 comprising inhibiting the interaction of poly(CUG)07-29-2010
20100029548GLYCOPROTEINS PRODUCED IN PLANTS AND METHODS OF THEIR USE - Methods of increasing the yield in plant expression of recombinant proteins comprising: engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein) for secretion. The methods result in increased recombinant glycosylated protein yields. Proteins produced according to these methods are disclosed.02-04-2010
20100029547Mvl, an antiviral protein from a cyanobacterium - The present invention relates, e.g., to an isolated polypeptide from a cyanobacterium, 02-04-2010
20100022444COMBINATION THERAPY FOR MODULATION OF ACTIVITY AND DEVELOPMENT OF CELLS AND TISSUES - The invention as disclosed herein provides methods and compositions for modulation of development and activities of cells and tissues in a subject in need of treatment thereof. The inventive methods and compositions involve the use of a combination therapy that comprises at least two active compositions, the first active composition comprising a balanced PC and an essential fatty acid composition and the second active composition comprising a growth factor, in a suitable carrier or diluent, wherein the combination therapy modulates development and activities of cells and tissues in the subject.01-28-2010
20090118165METHOD OF TREATING CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA - A method of treating chemotherapy-induced thrombocytopenia includes administering to a subject undergoing chemotherapy a therapeutically effective amount of a Bax-inhibiting peptide.05-07-2009
20080305990Method of Producing Fully Carbamylated Erythropoietin - The present invention relates to a method of carbamylating an erythropoietin such that the resulting carbamylated erythropoietin has less that about 10% free primary amines on the lysines and the N-terminal amino acids, is not digested when exposed to Lys-C proteolysis, exhibits no erythropoietic activity in a TF-1 or UT-7/EPOR cell viability assay at a concentration of 1 μg/ml, and demonstrates a static sciatic index of less than about 0.65 within a Sciatic Nerve Assay. Additionally, the invention is related to pharmaceutical compositions containing carbamylated erythropoietins of the invention and the use of the pharmaceutical compositions for the treatment of conditions and diseases of excitable tissues.12-11-2008
20100087363GLYCAN MODIFIED SOLUBLE RECEPTORS AND BINDING PROTEIN AND THEIR USE - An invention relates to a glycan-modified soluble receptor or binding protein of a cytokine, growth factor, lipoprotein or oxidized lipoprotein, modified to carry a terminal Gal, GlcNAc or GalNAc.04-08-2010
20090023636Methods and compositions for the prevention and treatment of anemia - Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.01-22-2009
20090088372Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof - The present disclosure relates to a novel enzymatic approach according to the invention using an unprecedented sortase-catalyzed transpeptidation reaction between a substrate comprising LPXTG peptide motif and biomolecules such as aminosugars, hydroxyamino acids, hydroxyamino acid esters, aminolipids, polyamines; nucleic acids or derivatives thereof, or any molecule having such moieties; or any compound having such moieties to obtain a bioconjugates useful for target delivery of a compound. The present disclosure provides bioconjugates obtained by the novel sortase catalysed transpeptidedation reaction.04-02-2009
20100222253METHODS FOR EXTRACTING PLATELETS AND COMPOSITIONS OBTAINED THEREFROM - This invention provides methods for extracting platelets, compositions obtained therefore, and methods for using the same.09-02-2010
20100216698LIQUID FORMULATIONS OF G-CSF - Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.08-26-2010
20090247450G-CSF LIQUID FORMULATION - The invention relates to G-CSF liquid formulations that have a long shelf-life and to methods for producing the same. The invention also relates to liquid formulations containing G-CSF as the active substance, acetate as the buffer substance, polysorbate 20 or polysorbate 80 as the surfactant and optionally pharmaceutically acceptable adjuvants, the formulations having a pH between 4.1 and 4.4.10-01-2009
20090239788RECOMBINANT OR TRANSGENIC FACTOR VII COMPOUND HAVING A MAJORITY OF GLYCAN, BIANTENNARY, BISIALYLATED AND NON-FUCOSYLATED FORMS - The present invention concerns a recombinant or transgenic factor VII compound, each factor VII molecule of the compound having glycan forms linked to N-glycosylation sites, wherein among all the factor VII molecules in said compound, glycan, biantennary, bisialylated and non-fucosylated forms are in the majority. The invention also concerns such a compound for use as a medication, and a method for preparing said compound, among others.09-24-2009
20100016218CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS - Disclosed herein are compositions and methods for the treatment of otic disorders with anti-apoptotic agent or pro-apoptotic agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).01-21-2010
20100137193CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH - Described herein are methods of inhibiting the growth of or killing a bacterium in an animal subject, preventing or delaying onset of an infection with a bacterium in an animal subject, preventing or delaying onset of a pathogen mediated disease or disorder in an animal subject, or reducing bacterial load in an animal subject, comprising administering an effective amount of a derivatized chitosan to the animal. Also described herein are preparations comprising a chitosan derivative for administration to an animal.06-03-2010
20100130406GLYCATED MILK AND USES THEREOF - Milk-based products and drinks are provided including specified forms of identified proteins or fragments thereof, as are methods for the use of such milk-based products and drinks in the promotion of sleep.05-27-2010
20090197796Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors - Methods are provided for treating HPG axis-positive cancers, preventing or slowing proliferation of cells of HPG axis-positive cancer origin, preventing HPG axis-positive cancers in a patient at risk of contracting such cancers, preventing or inhibiting an upregulation of the cell cycle in HPG axis-positive cancer-derived cells in a patient, and decreasing the level of HPG axis-positive cancer-specific markers in a patient.08-06-2009
20100234276ERYTHROPOIETIN SOLUTION PREPARATION - The present invention relates to an erythropoietin-containing solution preparation containing a poloxamer and having a pH of 6.5 to 7.5. The present invention also relates to a method for quantifying a protein in a trace amount, the method including the following steps: binding a protein sample to a high-intensity fluorescent dye; separating a desired analyte from the obtained sample by an appropriate separation means; and quantifying the desired analyte and converting the amount of the analyte into the amount of the protein.09-16-2010
20090258821Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window - Methods and uses are provided for a pharmaceutical composition with an erythropoietin or a tissue protective cytokine for protecting or restoring function to a responsive cell, tissue, organ or body part function or viability in mammals when administered outside of the therapeutic window of previously approved therapeutics.10-15-2009
20090036358Methods of preparing pharmaceutical compositions for treatment of factor Vlll associated disorders and methods of use - The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose.02-05-2009
20090149372BMP10 propeptides and related methods - In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10.06-11-2009
20100197567CONUS POLYPEPTIDES - The invention relates to peptides (termed propeller peptides herein) and related peptides (termed peptides of the G12.2 family herein), about 60 to about 90 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which blocks the desensitization of AMPA-type ionotropic glutamate receptors (AMPARs).08-05-2010
20090143280ANTI-CANCER COMBINATION TREATMENT AND KIT-OF-PARTS - In one aspect the present invention relates to pharmaceutical kits of parts suitable for treating neoplastic diseases such as cancer comprising an anti-cancer medicament, a Basidiomycete bioactive agent in solid or liquid form, and, optionally instructions for a dosing regime.06-04-2009
20100093609PRODRUGS OF TRICIRIBINE AND TRICIRIBINE PHOSPHATE - A prodrug composition is provided which includes a pharmaceutical species and an amino acid having a covalent bond to the pharmaceutical species. Particular pharmaceutical species are 6-amino-4-methyl-8-(beta.-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine, also known as TCN and by the trade name triciribine; as well as the 5′phosphate of triciribine. TCN and TCNP prodrugs of the present invention have increased bioavailability compared to the parent TCN and TCNP. The inventive prodrug is transported from the gastrointestinal lumen by a specific transporter and is enzymatically cleaved to yield TCN or TCNP, such that TCN or TCNP is delivered to the individual.04-15-2010
20100093608MODIFIED ANIMAL ERYTHROPOIETIN POLYPEPTIDES AND THEIR USES - Modified animal erythropoietin polypeptides and uses thereof are provide.04-15-2010
20090131304Semi-Synthetic Desmethyl-Vancomycin-Based Glycopeptides With Antibiotic Activity - Semi-synthetic glycopeptides that have antibacterial activity are based on modifications of the desmethyl-vancomycin scaffold, in particular, acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conversion of the acid moiety on the macrocyclic ring of this scaffolds to certain substituted amides. In addition, compounds of the invention include desmethyl-vancomycin scaffolds on which the acid moiety on the macrocyclic ring is converted to certain substituted amides and the amino substituent on the amino-substituted sugar moiety is alkylated with certain alkyl groups. Also provided are methods for synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections.05-21-2009
20090131305ALPHA-1 ANTITRYPSIN FOR TREATING EXACERBATION EPISODES OF PULMONARY DISEASES - The present invention relates to methods for the treatment of exacerbation periods of pulmonary diseases, particularly chronic obstructive pulmonary diseases, by administering alpha-1 antitrypsin (AAT) to a subject in need thereof. Particularly, the present invention discloses the efficient treatment of exacerbation periods of pulmonary diseases by administering AAT via inhalation.05-21-2009
20100210508Method for the Massive Culture of Cells Producing Recombinant Human Erythropoietin - The present invention relates, in general, to a method for the massive culture of recombinant mammalian cells for the production of recombinant human erythropoietin (EPO) in culture medium containing insulin. The present invention also refers to a method of producing EPO and to the EPO thus produced.08-19-2010
20100173830FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.07-08-2010
20100048458TRIBONECTINS - The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.02-25-2010
20100048456GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS - The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.02-25-2010
20090029906ERYTHROPOIETIN-DERIVED SHORT PEPTIDE AND ITS MIMICS AS IMMUNO/INFLAMMATORY MODULATORS - The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.01-29-2009
20100009902Glycoconjugation Using Saccharyl Fragments - The present invention provides conjugates between a substrate, e.g., peptide, glycopeptide, lipid, etc., and a modified saccharyl fragment bearing a modifying group such as a water-soluble polymer, therapeutic moiety or a biomolecule. The conjugates are linked via the enzymatic conversion of the activated modified saccharyl fragment into a glycosyl linking group that is interposed between and covalently attached to the substrate and the modifying group. The conjugates are formed from substrates by the action of a sugar transferring enzyme, e.g., a glycosyltransferase. For example, when the substrate is a peptide, the enzyme conjugates a modified saccharyl fragment moiety onto either an amino acid or glycosyl residue of the peptide. Also provided are pharmaceutical formulations that include the conjugates. Methods for preparing the conjugates are also within the scope of the invention.01-14-2010
20090062183Modulation of synaptogenesis - Soluble proteins, e.g. thrombospondins, can trigger synapse formation. Such proteins are synthesized in vitro and in vivo by astrocytes, which therefore have a role in synaptogenesis. These thrombospondins are only expressed in the normal brain exactly during the period of developmental synaptogenesis, being off in embryonic brain and adult brain but on at high levels in postnatal brain. Methods are provided for protecting or treating an individual suffering from adverse effects of deficits in synaptogenesis, or from undesirably active synaptogenesis. These findings have broad implications for a variety of clinical conditions, including traumatic brain injury, epilepsy, and other conditions where synapses fail to form or form inappropriately. Synaptogenesis is enhanced by contacting neurons with agents that are specific agonists or antagonists of thrombospondins. Conversely, synaptogenesis is inhibited by contacting neurons with inhibitors or antagonists of thrombospondins.03-05-2009
20090176696Methods And Compositions For Modulating An Immune Response - The present invention provides compositions and methods for the suppression of Th2-mediated immune response. Tracheal cytotoxin is shown to mediate a selective suppression of T helper cell type 2 (Th2)-mediated immune responses. The methods and compositions of the invention are useful for the treatment of Th2-mediated diseases and conditions due to their utility in suppressing Th2-mediated immune responses. The invention further extends to methods for suppressing the production of cytokines, such as IL-4 and IL-5 which contribute to the development of Th2-mediated immune responses.07-09-2009
20100190688Tetrapeptide analogs - Compounds, compositions and methods for treatment of hyperproliferative diseases, such as cancer are provided.07-29-2010
20080300174COMPOSITIONS AND METHODS FOR ENHANCING FACTOR VIII HEAVY CHAIN SECRETION - FVIII heavy chain mutants are provided which exhibit enhanced secretion from transfected cells and robust anti-coagulation activity.12-04-2008
20080300176METHODS OF TREATING NEURODEGENERATIVE DISEASES - The invention relates to the discovery that in an animal model of Parkinson's disease (PD), administration of granulocyte colony-stimulating factor (G-CSF) to rodents having 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD restored the function of dopamine neurons. In these animals, G-CSF treatment increased the number of dopamine neurons in the substantia nigra (SN), G-CSF treatment partially restored the nigrostriatal pathway, and G-CSF restored the function of dopamine to the level before MPTP treatment. The invention also relates to the discovery that treatment of a human patient with corticobasilar ganglionic degeneration, a rare progressive neurological disorder characterized by Parkinsonism and coritcal dysfunction, with G-CSF resulted in a significant improvement in the patient's Unified Parkinson's Disease Rating Scale evaluations as well as measures of activity of daily living. The invention further relates to the discovery that G-CSF treatment of a patient who had suffered an acute stroke resulted in a significant improvement in neurological function, the patient having minimal observable disability seven years later. The methods described herein can be used to treat PD in a mammalian subject (e.g., rodent, human) as well as other neurodegenerative diseases such as Alzheimer's disease, spinal cord injury, and stroke.12-04-2008
20080300175Glycopegylated erythropoietin - The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.12-04-2008
20080300173Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] - The present invention provides polypeptides that include an O-linked glycoconjugate in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. The polypeptides of the invention include wild-type peptides and mutant peptides that include an O-linked glycosylation site that is not present in the wild-type peptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response.12-04-2008
20100173829Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof - The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α07-08-2010
20100204087TRIBONECTINS - The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.08-12-2010
20090298747Methods and Compositions For Treatment of Nitric Oxide-Induced Clinical Conditions - The present invention provides compositions and methods for modulating cellular nitric oxide (NO) production and for treating a clinical condition associated therewith.12-03-2009
20090281022Method for Producing Factor VII Glycoforms - The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions.11-12-2009
20100234282SYSTEM FOR DELIVERING NUCLEIC ACIDS FOR SUPPRESSING TARGET GENE EXPRESSION BY UTILIZING ENDOGENOUS CHYLOMICRON - The object of present invention is to provide a system that can deliver in vivo nucleic acids such as an siRNA for suppressing a target gene expression in vivo more safely and efficiently, and to provide an expression-suppressing agent and a pharmaceutical composition utilizing the system. An introduction substance into chylomiclon, particularly nucleic acids to which an alpha-tocopherol is bound for suppressing a target gene expression, can be delivered more safely and efficiently into hepatic cells in vivo by administering the nucleic aids under the condition where the production of chylomicron is induced in the body. Alternatively, alpha-tocopherol-bound nucleic acids are mixed with extracted chylomiclon, and then they are administered. Consequently, a target gene expression is suppressed, thereby a disease caused by an elevated expression of the target gene can be treated more safely and efficiently.09-16-2010
20100234281ANTIBACTERIAL ANTISENSE OLIGONUCLEOTIDE AND METHOD - A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3′ or 5′ end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological pH. Also disclosed is an antisense oligonucleotide having enhanced antibacterial activity by virtue of one or both modifications.09-16-2010
20100234280ANTISENSE ANTIBACTERIAL METHOD AND COMPOUND - An antibacterial antisense conjugate and method of using the same for treating a bacterial infection in a mammalian host are disclosed. The conjugate includes an antisense oligonucleotide conjugated to a carrier peptide that significantly enhances the antibacterial activity of the oligonucleotide. The antisense oligonucleotide contains 10-20 nucleotide bases and has a targeting nucleic acid sequence complementary to a target sequence containing or within 10 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication, where the compound binds to a target mRNA with a T09-16-2010
20100234279Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same - The present invention relates to a soluble hydrophobic-core carrier composition comprising (i) a linear polymeric backbone; (ii) a plurality of hydrophilic polymeric protective chains covalently linked and pendant to the polymeric backbone and (iii) at least one hydrophobic moiety covalently linked and pendant to the polymeric backbone. In certain embodiments, the weight ratio of hydrophilic protective chains to hydrophobic moieties in the carrier is at least 15:1. In other embodiments, at least 90% of the residues of the polymeric backbone are coupled to a hydrophilic polymeric protective chain or a hydrophobic moiety. In other embodiments, the composition further comprises (iv) a hydrophobic load molecule dissociably linked to the hydrophobic moiety of the carrier.09-16-2010
20100234278PROPHYLACTIC AND/OR THERAPEUTIC AGENTS FOR PERIPHERAL NEUROPATHY - When a pharmaceutical composition for preventing and/or treating peripheral neuropathy caused by chromosomal microtubule inhibition, which comprises erythropoietin as an active ingredient, is administered to patients receiving a microtubule inhibitor as an anticancer agent, such treatment alleviates peripheral neuropathy in the patients and enables increased dosage, prolonged period and increased frequency for administration of the above anticancer agent, which were never before achieved. Thus, the pharmaceutical composition not only contributes to improvement of QOL in the patients, but also enables prolongation of life in the patients.09-16-2010
20100234277COADMINISTRATION OF ALPHA-FETOPROTEIN AND A DISEASE MODIFYING ANTI-RHEUMATIC DRUG FOR TREATING INFLAMMATORY ARTHRITIC DISEASE - The present invention relates to methods for treating an anti-inflammatory arthritic disease by coadministering therapeutically effective amounts of an alpha-fetoprotein (or a biologically active fragment thereof) and a disease modifying anti-rheumatic drug (DMARD) to a patient in need thereof. Also disclosed are compositions and kits that include therapeutically effective amounts of an alpha-fetoprotein (or a biologically active fragment thereof) and a DMARD.09-16-2010
20090118166Conditioned Decellularized Native Tissues for Tissue Restoration - The invention provides a composition conditioned for the remodeling, restoration, repair, or replacement of tissue within a host. The composition is conditioned by culturing cells on the matrix and/or by exposing the cultured cells or matrix to one or more stressors.05-07-2009
20100167992Phenyl Ester Side Chains to Increase Polymer Resorptivity - The present invention relates to polymers modified to increase their resorbability. In particular, the polymers of the invention have phenyl ester side chains which are good leaving groups and which thereby increase the resorption rate of the polymer relative to the same polymer, for example, bearing a comparable amount of an alkyl ester side chain. Such polymers are generally water insoluble, but when modified are able to solublize drugs and upon degradation and resorption, release those in a physiological environment in a controlled and/or sustained manner.07-01-2010
20080255035SPARC AND METHODS OF USE THEREOF - The invention provides methods of treating a mammalian tumors comprising combination therapy with SPARC polypeptides, an angiogenesis inhibitor and paclitaxel. The invention provides also methods of treating a mammalian tumors comprising combination therapy with SPARC polypeptides and paclitaxel. Further, the invention produces kits and methods to predict therapy responses.10-16-2008
20080255034Transdermal Delivery System for Treating Infertility - The transdermal delivery system for treating infertility in a patient comprises an apparatus (10-16-2008
20080249001AGENTS THAT ALLEVIATE SIDE-EFFECTS CAUSED BY CHEMOTHERAPY AGENTS - The present invention provides improving agents of side-effects of chemotherapy agents. Though the erythroid progenitor cells decrease due to the side-effect of chemotherapy agents, such side-effect can be improved by chemotherapy agents which comprise arginine as the active ingredient.10-09-2008
20090036360MEDICAMENT CONTAINING ACTIVATED ANTITHROMBIN III - The invention concerns the use of antithrombin III with a modified conformation which is referred to as activated antithrombin III (IDAAT=immune defence activated antithrombin) as a medicament.02-05-2009
20080234181ANTISENSE GUANIDINIUM PEPTIDE NUCLEIC ACID (GPNA) OLIGONUCLEOTIDES AS ANTITUMOR AGENTS - A class of antisense agents having a distributed guanidinium peptide nucleic acids (GPNA) backbone which has excellent uptake into mammalian cells, can bind to the target DNA or RNA in a highly sequence specific manner and can resist nucleases and proteases both outside and inside the cell(s) of interest. In one embodiment, either systemic or intratumoral administration of antisense Epidermal Growth Factor Receptor (“EGFR”) GPNA oligonucleotides is believed to downmodulate EGFR levels, thus in turn to reduce head and neck squamous cell carcinoma tumor growth, which has been confirmed to date both in vitro and in vivo.09-25-2008
20080234180Use of Sulgliocotide for the Treatment of Mucositis - Use of sulgliocotide in the treatment or prevention of mucositis.09-25-2008
20080227692Compositions and methods for treating ophthalmic disorders - The present invention relates to compositions and methods for treating and/or preventing ocular disorders, diseases or conditions and compositions and methods for treating or preventing ophthalmic conditions and disorders in a subject in need thereof.09-18-2008
20080227691Blood Coagulation FVIII Analogues - The invention is related to a FVIII analogue which has a circulation time in the blood stream before activation of at least about two times of that of native FVIII and a week after injection to a patient retains at least about 5% of the FVIII activity compared to the initial activity peak value reached after injection. The claimed FVIII analogues comprise a targeted disruption of one or more of the clearance sites in the FVIII molecule by introduction of at least one N-glycosylation site or by introduction of at least one Cys residue within or spatially close to the clearance site in the A2 domain or a combination thereof. The inserted cysteine residues may be further modified by conjugation with a chemical group increasing the molecular weight of the FVIII analogue.09-18-2008
20080221019Treatment of Inclusion Body Myositis - The present invention relates to the field of myopathy and particularly to the treatment and/or prevention of inclusion body myositis (IBM). A composition is provided, which comprises as an active ingredient either growth hormone, a secretagogue thereof or a mixture thereof, to cure IBM or suppress the symptoms associated therewith.09-11-2008
20100041584GEM DIFLUORINATED C-GLYCOPEPTIDES, THEIR PREPARATION AND THEIR USE FOR THE PRESERVATION OF BIOLOGICAL MATERIALS AND/OR IN CRYOSUGERY - The invention concerns a gem-difluorinated C-glycopeptide compound of formula (I) in which N is an integer between 1 and 5, R02-18-2010
20080200372Glycosaminoglycan Peptides Derived From Connective Tissues And Use Thereof In The Prevention Of Arthritis And Other Degenerative Medical Conditions - The inventors sought to provide compositions and methods of prophylaxis to prevent these harmful immune responses in patients and to prevent the related undesirable symptoms biological tissue such as for example inflammation, cell injury, tissue injury, tissue degradation, tenderness, redness, joint stiffness, joint swelling, restricted mobility and reduced strength. The inventors found that prophylactic therapy of an animal comprising administering a pharmaceutical composition comprising a GAG-peptide complex, optionally together with a connective tissue derived polypeptide, prevented the onset of at least one undesirable symptom.08-21-2008
20080261869COMPOSITIONS AND METHODS OF USE FOR ALPHA-1 ANTITRYPSIN HAVING NO SIGNIFICANT SERINE PROTEASE INHIBITOR ACTIVITY - Embodiments herein illustrate methods and compositions for treating medical disorders. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating a bacterial infection, or a viral infection in a subject. More particularly, embodiments herein relate to compounds including naturally occurring and synthetic compositions having alpha-1 antitrypsin activity but no significant serine protease inhibitor activity.10-23-2008
20090258822Diagnosis and Treatment of Age-Related Macular Degeneration - The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.10-15-2009
20100004161Toll Like Receptor 4 Dysfunction and the Biological Applications Thereof - The present invention relates to an in vitro method of assessing the sensitivity of a subject to a treatment of cancer, which method comprises detecting the presence of a mutated Toll Like Receptor 4 (TLR4) nucleic acid or an abnormal TLR4 protein expression or activity in a sample from the subject, the presence of said mutated TLR4 nucleic acid or abnormal TLR4 expression or activity being indicative of a resistance to said treatment. The invention further provides compounds for treating or preventing a cancer in a subject having a mutated TLR4 nucleic acid or an abnormal TLR4 protein expression or activity.01-07-2010

Patent applications in class Glycoprotein (carbohydrate containing)